+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

MASH Therapeutics and Diagnostics Market Outlook 2026-2034: By Offering, Diagnostic Method, Drug Status, Customer

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6291762
The MASH Therapeutics and Diagnostics Market is estimated at USD 6.7 billion in 2026 and is projected to reach USD 24.5 billion by 2034, growing at a CAGR of 17.6% during 2026-2034.

Market Overview

The MASH market covers indication-specific therapeutics and relevant diagnostic assessment, distinguishing authorized products from development programs. MASH care requires appropriate diagnosis and eligible treatment. Medicines and fibrosis-assessment tools have distinct roles.

Diagnostic uncertainty and access constrain uptake. Reliable testing and authorized therapy access support providers. National approvals and reimbursement shape markets. Product positioning depends on appropriate clinical evidence, local authorization and formulation availability, with access conditions differing between healthcare systems. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain. Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself. Commercial demand reflects the number of eligible treated patients, continuity of access and the medicines selected within established care pathways.

Key Takeaways

  • Demand drivers: MASH care requires appropriate diagnosis and eligible treatment. Disease stage governs utilization. Disease prevalence alone does not establish the revenue available to any particular medicine or supplier.
  • Technology and performance: Medicines and fibrosis-assessment tools have distinct roles. Approved uses differ from clinical development. Products within the same therapeutic area should not be treated as clinically interchangeable. Purchasing analysis separates originator and alternative products, where available, and considers how national access arrangements influence realized demand.
  • Challenges and economics: Diagnostic uncertainty and access constrain uptake. Broad metabolic disease prevalence overstates treated demand. Coverage, dispensing channels and reliable supply also influence whether appropriate treatment reaches eligible patients over time.
  • Commercial opportunities: Reliable testing and authorized therapy access support providers. Commercial opportunity depends on evidence and permitted uses. Formulation development and access initiatives require evaluation within the relevant national treatment and purchasing environment.
  • Geographic considerations: National approvals and reimbursement shape markets. Reimbursement, prescribing and distribution conditions can differ substantially between countries. International availability cannot be inferred solely from a product being marketed elsewhere.
  • Product and segment distinctions: Offering coverage includes Therapeutic Medicines, Diagnostic Products and Services and Research and Development Tools. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain.
  • Application and customer priorities: Diagnostic Method categories include Laboratory Tests, Imaging and Elastography, Biopsy and Histopathology and Other Assessment. Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations.
  • Purchasing and delivery: Purchasers compare evidence, indications and availability. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself. Product development is evaluated separately from medicines already available through authorized channels.
  • Competitive positioning: Madrigal Pharmaceuticals, Novo Nordisk and Viking Therapeutics are among the companies covered. The analysis distinguishes relevant product, technology and channel roles, with emphasis on application fit, supply capabilities and customer support.
  • Outlook priorities: The mash therapeutics and diagnostics outlook depends on the interaction of end-use demand, product qualification and commercially viable delivery. Reliable testing and authorized therapy access support providers. National approvals and reimbursement shape markets.

Competitive Landscape

MASH competition distinguishes authorized therapies, investigational medicines and diagnostic technologies. Madrigal and Novo Nordisk provide key authorized-therapy reference portfolios, while other businesses occupy specific research or diagnostic roles. Akero and 89bio coverage is consolidated within Novo Nordisk and Roche respectively rather than counted as additional independent parent groups. Comparison considers indication-specific evidence, patient eligibility, diagnostic assessment and access arrangements. Imaging and laboratory tools do not perform identical functions, and diagnostic use does not establish therapeutic benefit. The report separates current product availability from development programs and treats medicine revenue independently from testing equipment or service revenues.

Companies Mentioned

  • Madrigal Pharmaceuticals
  • Novo Nordisk
  • Viking Therapeutics
  • Roche
  • Inventiva
  • Alfasigma
  • Pfizer
  • Gilead Sciences
  • AstraZeneca
  • Echosens
  • Siemens Healthineers
  • GE HealthCare
  • Philips
  • Fujifilm
  • Hologic
  • Labcorp
  • Quest Diagnostics
  • Abbott

Market Segmentation: MASH Therapeutics and Diagnostics Market

By Offering

  • Therapeutic Medicines
  • Diagnostic Products and Services
  • Research and Development Tools

By Diagnostic Method

  • Laboratory Tests
  • Imaging and Elastography
  • Biopsy and Histopathology
  • Other Assessment

By Drug Status

  • Authorized Products
  • Clinical Development
  • Preclinical Research

By Customer

  • Care Providers
  • Diagnostic Laboratories
  • Biopharma and Research Users

MASH Therapeutics and Diagnostics Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

MASH Therapeutics and Diagnostics Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analysed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across the report’s covered markets.

Countries Covered

  • North America - MASH Therapeutics and Diagnostics Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - MASH Therapeutics and Diagnostics Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • BeNeLux
    • Russia
    • Sweden

  • Asia-Pacific - MASH Therapeutics and Diagnostics Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - MASH Therapeutics and Diagnostics Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - MASH Therapeutics and Diagnostics Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru
* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the MASH Therapeutics and Diagnostics value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

  • What are the current market size and outlook across the covered markets?
  • Which product and customer categories offer the most relevant opportunities?
  • How do supply conditions, pricing and competitive strategies affect market development?
  • Which risks and practical investment considerations should decision makers evaluate?

Your Key Takeaways from the MASH Therapeutics and Diagnostics Market Report

  • Global MASH Therapeutics and Diagnostics Market size and growth projections (CAGR), 2026-2034
  • Impact of geopolitical developments on MASH Therapeutics and Diagnostics trade, costs, and supply chains
  • MASH Therapeutics and Diagnostics Market size, share, and outlook across the 5 regions and country/subregional markets listed above, 2026-2034
  • MASH Therapeutics and Diagnostics Market size, CAGR, and market share of key products, applications, and end-user verticals, 2026-2034
  • Short- and long-term MASH Therapeutics and Diagnostics Market trends, drivers, restraints, and opportunities
  • Porter’s Five Forces analysis, technological developments, and MASH Therapeutics and Diagnostics supply chain analysis
  • MASH Therapeutics and Diagnostics trade analysis, MASH Therapeutics and Diagnostics Market price analysis, and MASH Therapeutics and Diagnostics supply/demand dynamics
  • Company profiles covering business overview, key strategies, financial information where available, and relevant products
  • Latest MASH Therapeutics and Diagnostics Market news and developments

This product will be delivered within 1-3 business days.

Table of Contents

1. MASH Therapeutics and Diagnostics Market - Executive Summary
1.1. Market Snapshot, 2026
1.2. Key Findings and Outlook, 2026-2034

2. MASH Therapeutics and Diagnostics Market - Market Scope and Research Methodology
2.1. Product and Service Definitions
2.2. Value Chain and Revenue Boundaries
2.3. Research Methodology and Forecast Assumptions

3. MASH Therapeutics and Diagnostics Market - Market Dynamics
3.1. Drivers, Trends and Opportunities
3.2. Constraints and Challenges

4. MASH Therapeutics and Diagnostics Market - Market Economics
4.1. Pricing and Procurement
4.2. Supply Chain and Relevant Policy Environment

5. MASH Therapeutics and Diagnostics Market - Market Size and Outlook, 2026-2034
5.1. Total Market Revenue
5.2. By Offering
5.3. By Diagnostic Method
5.4. By Drug Status
5.5. By Customer

6. MASH Therapeutics and Diagnostics Market - North America Market Outlook
6.1. Regional Revenue and Forecast
6.2. By Offering
6.3. By Diagnostic Method
6.4. By Drug Status
6.5. By Customer
6.6. Country Analysis

7. MASH Therapeutics and Diagnostics Market - Asia-Pacific Market Outlook
7.1. Regional Revenue and Forecast
7.2. By Offering
7.3. By Diagnostic Method
7.4. By Drug Status
7.5. By Customer
7.6. Country Analysis

8. MASH Therapeutics and Diagnostics Market - Europe Market Outlook
8.1. Regional Revenue and Forecast
8.2. By Offering
8.3. By Diagnostic Method
8.4. By Drug Status
8.5. By Customer
8.6. Country Analysis

9. MASH Therapeutics and Diagnostics Market - South and Central America Market Outlook
9.1. Regional Revenue and Forecast
9.2. By Offering
9.3. By Diagnostic Method
9.4. By Drug Status
9.5. By Customer
9.6. Country Analysis

10. MASH Therapeutics and Diagnostics Market - Middle East and Africa Market Outlook
10.1. Regional Revenue and Forecast
10.2. By Offering
10.3. By Diagnostic Method
10.4. By Drug Status
10.5. By Customer
10.6. Country Analysis

11. MASH Therapeutics and Diagnostics Market - Competitive Landscape
11.1. Companies Mentioned
11.2. Product and Service Portfolios
11.3. Supplier Positioning

12. MASH Therapeutics and Diagnostics Market - Strategic Developments and Outlook
12.1. Technology and Product Developments
12.2. Commercial Opportunities
12.3. Frequently Asked Questions

13. MASH Therapeutics and Diagnostics Market - Appendix
13.1. Definitions and Abbreviations
13.2. Sources and Forecast Assumptions

Companies Mentioned

  • Madrigal Pharmaceuticals
  • Novo Nordisk
  • Viking Therapeutics
  • Roche
  • Inventiva
  • Alfasigma
  • Pfizer
  • Gilead Sciences
  • AstraZeneca
  • Echosens
  • Siemens Healthineers
  • GE HealthCare
  • Philips
  • Fujifilm
  • Hologic
  • Labcorp
  • Quest Diagnostics
  • Abbott

Table Information